



Effect of surgical weight loss on insulin sensitivity and lipid profiles in MHO subjects.

Sufi P.¹

Malik S.N.², Lei S.², Casale C.², Heath D.¹, Gray R.¹,
Mohamed-Ali V.²

¹Whittington Hospital, North London Obesity Surgery Service (NLOSS), London, UK

²Adipokines and Metabolism Research Group, Research Division of Metabolism & Experimental Therapeutics, Division of Medicine, University College London, London, UK

Background - heterogeneity in obesity


- *Subsets of obese individuals, 20-30% of the Caucasian population, protected from obesity-associated metabolic abnormalities; the 'metabolically healthy but obese' (MHO). Primeau et al. 2011*
- *Display healthy metabolic profile, despite excessive body fat; normal insulin sensitivity, normal lipid and inflammatory profiles, no hypertension.*
- *Unlike the pathologically obese (PO), the metabolic profiles of MHO are comparable to normal weight subjects, with lower incidences of type 2 diabetes and cardiovascular diseases.*
- *Whether MHO individuals would gain any extra metabolic benefit from weight loss is unclear.*
- *Also no universally agreed definition of MHO as yet*

Objectives

- *to assess the effect of surgical weight loss on insulin sensitivity and lipid metabolism in MHO and PO subjects*

- *A simple, but, stringent, circulating biomarker to identify MHO*
- *Cross-sectional characterization of MHO versus PO, identified with this marker*
- *Effect of weight loss*

Schema of Study and definition of patients




Methods

- *Anthropometric measures* - Height (m), weight (kg), BMI $m \cdot kg^{-2}$, blood pressure, CPEX
- *Laboratory parameters* - lipid profile, inflammatory markers (IL-6, MCP-1), adipokines (adiponectin)
- *Insulin sensitivity* - fasting plasma glucose and serum insulin used to calculate HOMA-IR index - product of fasting plasma glucose (mmol/l) and insulin (mIU/L) divided by 22.5.

Baseline.....

- At baseline, using our criteria MHO ($n=24$) and PO ($n=53$) patients were identified and found to be matched for:
 - age (MHO vs. PO $40.6(9.5)$ vs $41.1(11.3)$ years,
 - body mass index, aerobic fitness, fasting plasma glucose, total-cholesterol, LDL-cholesterol and HDL-cholesterol.
- However, MHO patients had significantly lower systolic ($p=0.03$) and diastolic ($p=0.05$) blood pressure, circulating insulin levels ($p<0.001$) and triglycerides ($p<0.001$)
- MHO significantly more insulin sensitive ($0.84 \{0.59-1.2\}$ vs $2.4 \{1.7-4.1\}$, $p<0.001$) HOMA-IR index.

Following surgery ...




Significant weight loss in both groups 3-6 months post surgery.



	MHO			PO		
	Median	IQR25	IQR75	Median	IQR25	IQR75
FPG (mmol/L;Before)	5.10	3.90	5.90	5.10	4.65	5.95
FPG (mmol/L;After)	4.80	4.68	5.03	4.60	4.35	5.00
TC (mmol/L;Before)	3.50	3.08	4.03	4.20	3.10	4.70
TC (mmol/L;After)	4.15	3.68	4.65	4.40	4.10	5.00
LDL (mmol/L;Before)	1.90	1.80	2.35	2.40	1.88	2.87
LDL (mmol/L;After)	2.55	1.85	3.08	2.80	2.65	3.37
HDL (mmol/L;Before)	1.03	0.80	1.33	0.90	0.65	1.08
HDL (mmol/L;After)	1.15	1.05	1.50	1.11	0.95	1.20

In the Table: Red denotes significant change



Triglycerides



Systemic Insulin and insulin sensitivity



Adipokines/chemokines



Follow-up summary.....

- *At 3-6 months after surgery all patients lost weight significantly ($p < 0.001$).*
- *In the PO subjects this was associated with an increase in HDL-cholesterol ($p < 0.001$) and a significant reduction in plasma triglycerides, insulin and HOMA-IR.*
- *However, in the MHO group weight loss was accompanied by an increase in plasma total-cholesterol, triglycerides and insulin, as well as HOMA-IR.*
- *Adiponectin increased and MCP-1 decreased in both groups*

Conclusions

- *The metabolic effects of weight loss in MHO and PO patients appear to vary significantly.*
- *In the PO patients weight loss has the expected favourable metabolic profile.*
- *However, in MHO individuals, given their favorable metabolic profile prior to surgery, no additional metabolic gain is associated with weight loss.*
- *However, markers of adipose tissue health improved in both groups*

Discussion....

- *A single fasting serum glucose and insulin concentration is able to identify the MHO and PO cohorts described in this study*
- *Following weight loss there still appears to be heterogeneity in the response of these two groups, to some extent confirming recent results from Sesti et al., 2011*
- *However, more systemic anti-inflammatory (adiponectin) and less pro-inflammatory (MCP-1) adipokines after weight loss in both groups suggest improved adipose tissue health*
- *Thus, much of the MHO/PO phenotype may be mediated by differences resident in the skeletal muscle and/or liver*

Funding

European Commission FP6 - EXGENESIS
(LSHM - CT- 2004 - 005272)



The Whittington Hospital **NHS**
NHS Trust

Translational Research Small Grants Scheme